Table 1.
Sociodemographic profile.
| LDN+tDCS | LDN + tDCS Sham | Placebo+tDCS | Placebo + tDCS Sham | p-value | |
|---|---|---|---|---|---|
| Age (y) | 49.74 ± 1.97 | 48.09 ± 1.56 | 50.57 ± 2.23 | 48.95 ± 2.08 | 0.800a |
| Scholarship (y) | 10.00 ± 0.53 | 11.55 ± 0.99 | 13.00 ± 0.92 | 11.95 ± 0.83 | 0.097a |
| BMI (kg.m−2) | 27.44 ± 0.88 | 30.08 ± 1.30 | 28.37 ± 1.08 | 27.37 ± 0.87 | 0.236a |
| Use of Alcohol | 0.465b | ||||
| Yes | 33.3% | 13.6% | 18.2% | 14.3% | |
| No | 66.7% | 86.4% | 81.8% | 85.7% | |
| Smoking | 0.744b | ||||
| Yes | 19% | 18.2% | 9.1% | 9.5% | |
| No | 81% | 81.8% | 90.9% | 90.5% | |
| Use of medicine | |||||
| Tricyclic AD | 23.8% | 18.2% | 22.7% | 23.8% | 0.953b |
| Serotonergic AD | 33.3% | 27.3% | 18.2% | 14.3% | 0.523b |
| MAO Inhibitor | 0% | 4.5% | 0% | 0% | 1.000b |
| Antipsychotic | 0% | 0% | 4.5% | 0% | 1.000b |
| Anxiolytic | 19% | 4.5% | 9.1% | 23.8% | 0.302b |
| Carbamazepine | 0% | 4.5% | 0% | 0% | 0.948b |
| Valproic Acid | 0% | 0% | 0% | 4.8% | 0.500b |
AD, Antidepressive; BMI, Body Mass Index; LDN, Low-Dose of Naltrexone; MAO, Mono-Amino Oxidase.
a
One-Way ANOVA – Data expressed as mean ± standard error.
b
Fisher's Exact Test – Data expressed as percentage.